Arterolane at daily doses of 100 and 200 mg is a rapidly acting, effective, and safe synthetic antimalarial drug, which may potentially represent an alternative to artemisinin derivatives in antimalarial combination therapy.
In this issue of Clinical Infectious Diseases, d’Acremont et al  importantly address the clinical safety of withholding antimalarial treatment in febrile children who have a negative result for one of the newly developed rapid diagnostic tests (RDTs) for malaria.
Artemisinin-based combination therapies, including artesunate (AS) + amodiaquine (AQ), are the currently recommended first-line treatment of uncomplicated falciparum malaria. Fixed-dose co-formulations offer logistic and adherence advantages.
An integrated approach aimed at improving understanding and treatment of malaria has led to tangible improvements in terms of people's actions for the treatment of malaria. However, progress was hindered by the low availability of the first-line treatment after the switch to ACT.
The public health and private retail sector are important complementary sources of treatment in rural Tanzania. Ensuring the availability of ALu in the private retail sector is important for its successful uptake.
The differences in malaria treatment expenditures from consumers’ and providers’ perspectives point to high levels of informal payments, which worsen the economic burden of the disease and may predispose to catastrophic health spending.